Invion is trading at 0.15 as of the 16th of December 2024. This is a 21.05 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.15. Invion has over 57 % chance of experiencing financial distress in the next 2 years of operation, but had a somewhat good returns during the last 90 days. Invion has reported 100 for 1 split on 20th of November 2024. The performance scores are derived for the period starting the 16th of November 2024 and ending today, the 16th of December 2024. Click here to learn more.
Invion Limited, a clinical-stage drug development company, develops treatments for inflammatory diseases in Australia and the United States. It has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. The company has 4.21 B outstanding shares. More on Invion Limited
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Invion's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Invion or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Invion Limited (7C8) is traded on Frankfurt Exchange in Germany and employs 2 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 645.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Invion's market, we take the total number of its shares issued and multiply it by Invion's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Invion Limited classifies itself under Healthcare sector and is part of Drug Manufacturers - Specialty & Generic industry. The entity has 4.21 B outstanding shares.
Invion Limited has accumulated about 2.14 M in cash with 522.62 K of positive cash flow from operations.
Check Invion Probability Of Bankruptcy
Invion Limited Risk Profiles
Although Invion's alpha and beta are two of the key measurements used to evaluate Invion's performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in Invion without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Global Markets Map Now
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Invion financial ratios help investors to determine whether Invion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Invion with respect to the benefits of owning Invion security.